-
Something wrong with this record ?
Transgelin is upregulated in stromal cells of lymph node positive breast cancer
M. Dvořáková, J. Jeřábková, I. Procházková, J. Lenčo, R. Nenutil, P. Bouchal,
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Stromal Cells metabolism pathology MeSH
- Humans MeSH
- Lymph Nodes metabolism pathology MeSH
- Microfilament Proteins metabolism MeSH
- Biomarkers, Tumor metabolism MeSH
- Neoplasm Proteins metabolism MeSH
- Breast Neoplasms metabolism pathology MeSH
- Pilot Projects MeSH
- Gene Expression Regulation, Neoplastic MeSH
- Neoplasm Grading MeSH
- Muscle Proteins metabolism MeSH
- Up-Regulation MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
UNLABELLED: Transgelin and transgelin-2 have been discussed as potential markers of various cancers. Here we identified increased transgelin level in lymph node positive vs. negative, low grade primary breast cancer tissues using 2-DE in the cohort of 12 patients. We further clinically validated 2-DE results in an independent cohort of 48 low grade breast cancer patients through untargeted and targeted proteomics analysis (iTRAQ-2D-LC-MS/MS, mTRAQ-SRM), at transcript level and using immunohistochemistry. Another group of 48 high grade tumors of different breast cancer subtypes was analyzed together with the low grade samples to test transgelin specificity for low grade tumors and to study transgelin relation to known molecular markers and histological features. The results confirmed transgelin connection with the lymph node metastasis. As a marker of a reactive tumor stroma, transgelin can be connected with the higher risk of metastasis development. Moreover, we observed significant down-regulation of transgelin in high vs. low grade tumors caused by decreased content of stromal cells (mainly expressing transgelin) in high grade tumor tissue. We also analyzed expression of transgelin-2 in the second cohort using proteomics and immunohistochemistry. Transgelin-2 was mainly expressed by epithelial cancer cells and its levels were increased in metastatic and poorly differentiated tumors. BIOLOGICAL SIGNIFICANCE: Both transgelin and transgelin-2 have been previously described as potential markers of many types of cancer. We are specifying this connection to metastatic affection of lymph nodes and cell differentiation in breast cancer. In the wider context, the results of our study highlight tumor stroma as a source of cancer biomarkers and point out how measured levels of tissue markers can actually reflect cellular feature of cancer mass.
Department of Biochemistry Faculty of Science Masaryk University Brno Czech Republic
Masaryk Memorial Cancer Institute Regional Centre for Applied Molecular Oncology Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16027863
- 003
- CZ-PrNML
- 005
- 20190204090830.0
- 007
- ta
- 008
- 161005s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jprot.2015.11.025 $2 doi
- 024 7_
- $a 10.1016/j.jprot.2015.11.025 $2 doi
- 035 __
- $a (PubMed)26639304
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Dvořáková, Monika $u Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic; Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 245 10
- $a Transgelin is upregulated in stromal cells of lymph node positive breast cancer / $c M. Dvořáková, J. Jeřábková, I. Procházková, J. Lenčo, R. Nenutil, P. Bouchal,
- 520 9_
- $a UNLABELLED: Transgelin and transgelin-2 have been discussed as potential markers of various cancers. Here we identified increased transgelin level in lymph node positive vs. negative, low grade primary breast cancer tissues using 2-DE in the cohort of 12 patients. We further clinically validated 2-DE results in an independent cohort of 48 low grade breast cancer patients through untargeted and targeted proteomics analysis (iTRAQ-2D-LC-MS/MS, mTRAQ-SRM), at transcript level and using immunohistochemistry. Another group of 48 high grade tumors of different breast cancer subtypes was analyzed together with the low grade samples to test transgelin specificity for low grade tumors and to study transgelin relation to known molecular markers and histological features. The results confirmed transgelin connection with the lymph node metastasis. As a marker of a reactive tumor stroma, transgelin can be connected with the higher risk of metastasis development. Moreover, we observed significant down-regulation of transgelin in high vs. low grade tumors caused by decreased content of stromal cells (mainly expressing transgelin) in high grade tumor tissue. We also analyzed expression of transgelin-2 in the second cohort using proteomics and immunohistochemistry. Transgelin-2 was mainly expressed by epithelial cancer cells and its levels were increased in metastatic and poorly differentiated tumors. BIOLOGICAL SIGNIFICANCE: Both transgelin and transgelin-2 have been previously described as potential markers of many types of cancer. We are specifying this connection to metastatic affection of lymph nodes and cell differentiation in breast cancer. In the wider context, the results of our study highlight tumor stroma as a source of cancer biomarkers and point out how measured levels of tissue markers can actually reflect cellular feature of cancer mass.
- 650 _2
- $a nádorové biomarkery $x metabolismus $7 D014408
- 650 _2
- $a nádory prsu $x metabolismus $x patologie $7 D001943
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfatické uzliny $x metabolismus $x patologie $7 D008198
- 650 _2
- $a mikrofilamentové proteiny $x metabolismus $7 D008840
- 650 _2
- $a svalové proteiny $x metabolismus $7 D009124
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a nádorové proteiny $x metabolismus $7 D009363
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a buňky stromatu $x metabolismus $x patologie $7 D017154
- 650 _2
- $a upregulace $7 D015854
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jeřábková, Jarmila $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Procházková, Iva $u Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic.
- 700 1_
- $a Lenčo, Juraj $u Institute of Molecular Pathology, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic.
- 700 1_
- $a Nenutil, Rudolf $u Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic.
- 700 1_
- $a Bouchal, Pavel, $u Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic; Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic. Electronic address: bouchal@mou.cz. $d 1975- $7 xx0128495
- 773 0_
- $w MED00166847 $t Journal of proteomics $x 1876-7737 $g Roč. 132, č. - (2016), s. 103-11
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26639304 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20190204091107 $b ABA008
- 999 __
- $a ok $b bmc $g 1166177 $s 952493
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 132 $c - $d 103-11 $e 20151127 $i 1876-7737 $m Journal of proteomics $n J Proteomics $x MED00166847
- LZP __
- $a Pubmed-20161005
